{"id":"https://openalex.org/W2170804912","doi":"https://doi.org/10.1016/s0149-2918(01)80132-6","title":"Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir","display_name":"Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir","publication_year":2001,"publication_date":"2001-10-01","ids":{"openalex":"https://openalex.org/W2170804912","doi":"https://doi.org/10.1016/s0149-2918(01)80132-6","mag":"2170804912","pmid":"https://pubmed.ncbi.nlm.nih.gov/11726000"},"language":"en","primary_location":{"id":"doi:10.1016/s0149-2918(01)80132-6","doi":"https://doi.org/10.1016/s0149-2918(01)80132-6","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0149-2918(01)80132-6","pdf_url":null,"source":{"id":"https://openalex.org/S185879095","display_name":"Clinical Therapeutics","issn_l":"0149-2918","issn":["0149-2918","1879-114X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052775622","display_name":"Seth Hetherington","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Seth Hetherington","raw_affiliation_strings":["HIV/OI Clinical Development, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA. svh31379@glaxowellcome","GlaxoSmithKline, Research Triangle Park, North Carolina, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"HIV/OI Clinical Development, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA. svh31379@glaxowellcome","institution_ids":["https://openalex.org/I4210114143"]},{"raw_affiliation_string":"GlaxoSmithKline, Research Triangle Park, North Carolina, U.S.A","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072027358","display_name":"Sue McGuirk","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Sue McGuirk","raw_affiliation_strings":["GlaxoSmithKline, Greenford, Middlesex, England"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Greenford, Middlesex, England","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057176214","display_name":"Gwendolyn Powell","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gwendolyn Powell","raw_affiliation_strings":["GlaxoSmithKline, Research Triangle Park, North Carolina, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Research Triangle Park, North Carolina, U.S.A","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085142733","display_name":"Amy G. Cutrell","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amy Cutrell","raw_affiliation_strings":["GlaxoSmithKline, Research Triangle Park, North Carolina, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Research Triangle Park, North Carolina, U.S.A","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091035436","display_name":"Odin J. Naderer","orcid":"https://orcid.org/0009-0002-0809-274X","observed_orcids":["https://orcid.org/0009-0002-0809-274X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Odin Naderer","raw_affiliation_strings":["GlaxoSmithKline, Research Triangle Park, North Carolina, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Research Triangle Park, North Carolina, U.S.A","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014000664","display_name":"Bill Spreen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bill Spreen","raw_affiliation_strings":["GlaxoSmithKline, Research Triangle Park, North Carolina, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Research Triangle Park, North Carolina, U.S.A","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035268120","display_name":"Steve Lafon","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Steve Lafon","raw_affiliation_strings":["GlaxoSmithKline, Research Triangle Park, North Carolina, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Research Triangle Park, North Carolina, U.S.A","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110096019","display_name":"Gill Pearce","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Gill Pearce","raw_affiliation_strings":["GlaxoSmithKline, Greenford, Middlesex, England"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Greenford, Middlesex, England","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111923574","display_name":"Helen M. Steel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Helen Steel","raw_affiliation_strings":["GlaxoSmithKline, Greenford, Middlesex, England"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Greenford, Middlesex, England","institution_ids":["https://openalex.org/I188950975"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5052775622"],"corresponding_institution_ids":["https://openalex.org/I4210114143"],"apc_list":{"value":4240,"currency":"USD","value_usd":4240},"apc_paid":null,"fwci":8.3554,"has_fulltext":false,"cited_by_count":413,"citation_normalized_percentile":{"value":0.98039769,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":100},"biblio":{"volume":"23","issue":"10","first_page":"1603","last_page":"1614"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.002099999925121665,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/abacavir","display_name":"abacavir","score":0.9380000233650208},{"id":"https://openalex.org/keywords/hypersensitivity","display_name":"hypersensitivity","score":0.9300000071525574},{"id":"https://openalex.org/keywords/drug-reaction-with-eosinophilia-and-systemic-symptoms","display_name":"DRESS syndrome","score":0.6610000133514404},{"id":"https://openalex.org/keywords/nucleoside-reverse-transcriptase-inhibitors","display_name":"nucleoside reverse transcriptase inhibitors","score":0.9539999961853027},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.6470000147819519},{"id":"https://openalex.org/keywords/rechallenge","display_name":"drug rechallenge","score":0.7689999938011169},{"id":"https://openalex.org/keywords/hypotension","display_name":"hypotension","score":0.6140000224113464},{"id":"https://openalex.org/keywords/antiretroviral-therapy","display_name":"antiretroviral therapy","score":0.8119999766349792},{"id":"https://openalex.org/keywords/hiv-infection","display_name":"HIV infection","score":0.6399999856948853},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.44999998807907104},{"id":"https://openalex.org/keywords/mortality","display_name":"mortality","score":0.36000001430511475},{"id":"https://openalex.org/keywords/skin-rash","display_name":"rash","score":0.367000013589859},{"id":"https://openalex.org/keywords/dyspnea","display_name":"dyspnea","score":0.7369999885559082},{"id":"https://openalex.org/keywords/pharyngitis","display_name":"pharyngitis","score":0.7730000019073486},{"id":"https://openalex.org/keywords/gastrointestinal-symptoms","display_name":"gastrointestinal symptoms","score":0.6679999828338623},{"id":"https://openalex.org/keywords/fever","display_name":"fever","score":0.5630000233650208},{"id":"https://openalex.org/keywords/malaise","display_name":"malaise","score":0.39100000262260437}],"concepts":[{"id":"https://openalex.org/C2779465607","wikidata":"https://www.wikidata.org/wiki/Q304330","display_name":"Abacavir","level":5,"score":0.9798176288604736},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.936916172504425},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.7240373492240906},{"id":"https://openalex.org/C2775832928","wikidata":"https://www.wikidata.org/wiki/Q407954","display_name":"Expanded access","level":2,"score":0.5789380669593811},{"id":"https://openalex.org/C2779277585","wikidata":"https://www.wikidata.org/wiki/Q2673323","display_name":"Malaise","level":2,"score":0.5402374863624573},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5003275871276855},{"id":"https://openalex.org/C2777351918","wikidata":"https://www.wikidata.org/wiki/Q421559","display_name":"Reverse-transcriptase inhibitor","level":5,"score":0.48593559861183167},{"id":"https://openalex.org/C2777447569","wikidata":"https://www.wikidata.org/wiki/Q422606","display_name":"Didanosine","level":5,"score":0.47653064131736755},{"id":"https://openalex.org/C2779802037","wikidata":"https://www.wikidata.org/wiki/Q40878","display_name":"Diarrhea","level":2,"score":0.4757221043109894},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.4202921390533447},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.402154803276062},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.34827709197998047},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.3206602931022644},{"id":"https://openalex.org/C2777869810","wikidata":"https://www.wikidata.org/wiki/Q422631","display_name":"Lamivudine","level":4,"score":0.19643405079841614},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.17881232500076294},{"id":"https://openalex.org/C2780216070","wikidata":"https://www.wikidata.org/wiki/Q198504","display_name":"Zidovudine","level":4,"score":0.13660776615142822},{"id":"https://openalex.org/C2776452011","wikidata":"https://www.wikidata.org/wiki/Q311463","display_name":"Sida","level":4,"score":0.1249915361404419},{"id":"https://openalex.org/C2780727368","wikidata":"https://www.wikidata.org/wiki/Q1928978","display_name":"Viral disease","level":3,"score":0.11983343958854675},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.08411893248558044},{"id":"https://openalex.org/C120665830","wikidata":"https://www.wikidata.org/wiki/Q14620","display_name":"Optics","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C2780593183","wikidata":"https://www.wikidata.org/wiki/Q6844","display_name":"Hepatitis B virus","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000099227","descriptor_name":"Abacavir","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004342","descriptor_name":"Drug Hypersensitivity","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":true},{"descriptor_ui":"D004342","descriptor_name":"Drug Hypersensitivity","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D004342","descriptor_name":"Drug Hypersensitivity","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011358","descriptor_name":"Product Surveillance, Postmarketing","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015224","descriptor_name":"Dideoxynucleosides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D015224","descriptor_name":"Dideoxynucleosides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015994","descriptor_name":"Incidence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/s0149-2918(01)80132-6","doi":"https://doi.org/10.1016/s0149-2918(01)80132-6","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0149-2918(01)80132-6","pdf_url":null,"source":{"id":"https://openalex.org/S185879095","display_name":"Clinical Therapeutics","issn_l":"0149-2918","issn":["0149-2918","1879-114X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Therapeutics","raw_type":"journal-article"},{"id":"pmid:11726000","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11726000","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":35,"referenced_works":["https://openalex.org/W28488281","https://openalex.org/W1834076226","https://openalex.org/W1969618788","https://openalex.org/W1975904080","https://openalex.org/W1993086185","https://openalex.org/W2002263828","https://openalex.org/W2005284126","https://openalex.org/W2008175048","https://openalex.org/W2021918026","https://openalex.org/W2023754591","https://openalex.org/W2025113832","https://openalex.org/W2032451005","https://openalex.org/W2036752080","https://openalex.org/W2045444507","https://openalex.org/W2047166639","https://openalex.org/W2075208354","https://openalex.org/W2076661568","https://openalex.org/W2099214387","https://openalex.org/W2120615742","https://openalex.org/W2129710521","https://openalex.org/W2132767567","https://openalex.org/W2146431647","https://openalex.org/W2165253161","https://openalex.org/W2168733361","https://openalex.org/W2168871876","https://openalex.org/W2306573698","https://openalex.org/W2315214054","https://openalex.org/W2317624504","https://openalex.org/W2329100179","https://openalex.org/W2331028753","https://openalex.org/W2400098770","https://openalex.org/W2611915097","https://openalex.org/W2732136689","https://openalex.org/W3105329056","https://openalex.org/W4235030794"],"related_works":["https://openalex.org/W7035801758","https://openalex.org/W2130470659","https://openalex.org/W4252330854","https://openalex.org/W2413165419","https://openalex.org/W2016211303","https://openalex.org/W2402646829","https://openalex.org/W2059202889","https://openalex.org/W2323183682","https://openalex.org/W2279618556","https://openalex.org/W1996576357"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":17},{"year":2021,"cited_by_count":13},{"year":2020,"cited_by_count":10},{"year":2019,"cited_by_count":22},{"year":2018,"cited_by_count":9},{"year":2017,"cited_by_count":18},{"year":2016,"cited_by_count":20},{"year":2015,"cited_by_count":19},{"year":2014,"cited_by_count":13},{"year":2013,"cited_by_count":23},{"year":2012,"cited_by_count":24}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}